Microvascular and Antiinflammatory Effects of Rivaroxaban Compared to Aspirin in Type-2 Diabetic Patients With Subclinical Inflammation and High Cardiovascular Risk

NCT02164578 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

179

Enrollment

OTHER

Sponsor class

Conditions

Type 2 Diabetic Patients

Interventions

DRUG: Rivaroxaban
DRUG: Aspirin

Sponsor

GWT-TUD GmbH